Stocks | | | One of the things that made this correction so scary was that traditional safe-haven assets were not immune. While the S&P 500 (SPY) sank upwards of 30% stocks in the real estate, consumer staples, and utility sectors fell Read the Full Story |
|
From Our PartnersStock are dead (for now). Luckily we've discovered an alternative...
An investment that's nearly 10x more profitable than stocks, but yet has nothing to do with the stock market.
In fact, this under the radar market is responsible for the most profitable investment of all time! | | Click here for details >> |
|
Markets | | | Conagra’s push to streamline its portfolio has put it in a good position to benefit from pantry-loading. The global coronavirus pandemic is spurring a shift in consumer habits that are boosting demand. Read the Full Story |
|
Stocks | | | It's been a terrible few months for Macy's (NYSE: M). Sure, the stock had a decent holiday turnout, and things were looking reasonably bright going into one of the normally slowest shopping periods of the year Read the Full Story |
|
Markets | | | after a decade-long 600% rally, shares of Wendy’s (NASDAQ: WEN) began a fast and furious 90% selloff. In less than two years, they were back trading at 1992 levels and things were looking grim for the queen of the square burger. Read the Full Story |
|
Markets | | | Fitness center operator Planet Fitness (NASDAQ: PLNT) shares reached all-time highs at $88.77 on Feb. 19, 2020, just before global financial markets got blindsided by the coronavirus black swan. The S&P 500 (NYSEARCA: SPY)collapsed (-35%) in just under a month underscoring the fastest tran... Read the Full Story |
|
From Our PartnersEric Fry, one of America's top Investment Strategists, provides his latest report 5 Tech Stocks Set for 1,000% Gains after the Coronavirus Sell off. You can't afford to miss out on the once in a decade chance to buy after the recent 25% dip in the markets. Download this hot-off-the-presses research report now. | | It's yours FREE. |
|
The Early Bird Stock Of The Day Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests in Canada, Switzerland, Ireland, Denmark, Germany, the United States, and internationally. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of patients with adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as endocrinology and oncology indications; AEZS-150, a delayed clearance parathyroid hormone fusion polypeptide that is in preclinical trial for the treatment of chronic hypoparathyroidism; and AEZS-130 that is in preclinical trial for the treatment of amyotrophic lateral sclerosis. The company also has a license and research agreement with University of Wuerzburg to develop, manufacture, and commercialize AIM biologicals for the treatment of neuromyelitis optica spectrum disorder; and for pre-clinical development towards the potential treatment of Parkinson's disease. In addition, it has a license agreement with Consilient Health Ltd. and NK MEDITECH Ltd. for the development and commercialization of macimorelin; a distribution and commercialization agreement with Er-Kim Pharmaceuticals Bulgaria Eood for the commercialization of macimorelin for the diagnosis of growth hormone deficiency in children and adults; as well as The University of Sheffield, the United Kingdom for the development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of chronic hypoparathyroidism. Aeterna Zentaris Inc. was incorporated in 1990 and is headquartered in Toronto, Canada. | | View Today's Stock Pick |
|
